Form 4: Regeneron EVP Marion McCourt Executes Stock Sale Under 10b5-1 Plan

Marion McCourt, EVP Commercial at Regeneron Pharmaceuticals, sold 250 shares of common stock on April 1, 2024, under a pre-arranged 10b5-1 trading plan.

Summary

• Marion McCourt, EVP Commercial at Regeneron Pharmaceuticals, executed a sale of 250 shares of common stock on April 1, 2024.
• The transaction was conducted at a price of $964.73 per share.
• The sale was made under a pre-arranged trading plan (Rule 10b5-1(c)) adopted on February 16, 2023.
• Following the transaction, McCourt directly owns 13,181 shares of Regeneron common stock and indirectly owns 158 shares through a 401(k) plan.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing detailing a stock sale by an executive. It doesn't inherently convey positive or negative sentiment about the company's prospects.

Future Outlook

The document does not contain any specific forward-looking statements regarding the company's future performance.

Industry Context

Executive stock sales are a common occurrence in publicly traded companies. The use of 10b5-1 plans allows insiders to sell shares at predetermined times to avoid accusations of trading on inside information. This transaction provides insight into executive compensation and stock ownership at Regeneron.

Stakeholder Impact

• The stock sale may have a minor impact on shareholders, potentially creating slight downward pressure on the stock price in the short term.
• The transaction does not directly impact employees, customers, suppliers, or creditors.

Key Dates